Sanofi US
Part of Sanofi
CompanyUnited States
Sanofi US develops one asset, approved (lixisenatide in type 2 diabetes). Mostly peptide acting on GLP1R; based in the United States.
- 1
- Asset
- Furthest stage
- Approved
- 0
- Trials
- 12
- Signals
Pipeline
1Glucagon-like peptide-1 (GLP-1) receptor agonist improving glycemic control
Approved, Peptide, GLP1R, type 2 diabetes, acute coronary syndrome (Phase 3)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Signals20
- Similar companies6
Papers
Advances in therapy, Oct 28, 2019